Archive Tag: 100k Study

On November 24, 2017, Fox News reported on the UCLA Depression Grand Challenge’s (DGC) efforts to eradicate depression by the end of the century. In the news segment, Claudia Cowan, a FOX News Channel (FNC) San Francisco-based correspondent, reports on the 100k study and interviews Dr. Nelson Freimer, director of the DGC. The study is designed to unlock the genetic, Read more

Through the initiative, UCLA experts are identifying specific mechanisms that put people at risk for depression and creating customized suites of treatments for each patient.
UCLA Health

The UCLA Depression Grand Challenge (DGC) has come a long way since its initial annoucement last October 2015. The initiative is tackling depression in an unprecedented manner with an aim to better understand and treat this devastating disease. One year later, the DGC has begun a series of studies and set a program in Read more

An overview of the Depression Grand Challenge human studies demonstration projects that are underway

At the center of the Depression Grand Challenge (DGC) is a 10-year “100K Study,” in which researchers will monitor 100,000 people with the aim of identifying the genetic and environmental causes of depression.

The 100K Study will screen for depression, analyze participants’ genetics, measure early adversity and life stress and assess symptoms through remote monitoring using cell phones and wearable devices. In preparation for each of the facets of the 100K Study, demonstration projects are underway. Each demonstration study involves human participants. Explore the Guide to human studies demonstration projects to learn more about current and anticipated studies.

Read more

Depression research on a big scale: UCLA’s Depression Grand Challenge

The Depression Grand Challenge is tackling depression in an unprecedented manner and most notably sets itself apart by following a unique multidisciplinary and large-scale approach.  Dr. Jonathan Flint, author of the largest genetics study to date, joined the UCLA Depression Grand Challenge team earlier this year. Dr. Flint is one of four directors of the study and notes the study’s novel approaches to funding that may potentially utilize a stakeholder science where participants pay to enroll in a study.  With this method, both participants and researchers will benefit from the genetic sequencing employed in the study.

Read more at David Geffen School of Medicine